• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Veracyte Inc.

    6/10/26 4:17:11 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email
    S-8 1 vcyt-06102026xs8.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 10, 2026
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ____________________
    VERACYTE, INC.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    20-5455398
     (I.R.S. Employer
    Identification No.)
    6000 Shoreline Court, Suite 300
    South San Francisco, California
    (Address of Principal Executive Offices)
    94080
    (Zip Code)
    Veracyte, Inc. 2023 Equity Incentive Plan
    (Full title of the plan)
    Marc Stapley
    Chief Executive Officer
    6000 Shoreline Court, Suite 300
    South San Francisco, California
    (Name and address of agent for service)
    (650) 243-6300
    (Telephone number, including area code, of agent for service)
    Copies to:

    Jim Krenn, Esq.
    Morrison & Foerster LLP
    12531 High Bluff Drive
    San Diego, CA 92130
    (858) 720-5100

    Emily Beers, Esq.
    Morrison & Foerster LLP
    2100 L Street NW, Suite 900
    Washington, D.C. 20037
    (202) 887-1500
    Annie McGuire, Esq.
    Executive Vice President and
    General Counsel
    Veracyte, Inc.
    6000 Shoreline Court, Suite 300
    South San Francisco, CA 94080
    (650) 243-6300

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐





    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐






    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Veracyte, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 3,500,000 additional shares (the “Share Increase”) of the Registrant’s common stock, par value $0.001 per share (the “common stock”), available for issuance under the Registrant’s 2023 Equity Incentive Plan, as amended (the “2023 Plan”). At the Registrant’s Annual Meeting of Stockholders held on June 10, 2026, the Registrant’s stockholders, among other things, approved the Share Increase under the 2023 Plan.

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2023 Plan, this Registration Statement hereby incorporates by reference the contents of (i) the Registrant’s Registration Statements on Form S-8 filed with the Commission on October 30, 2013 (File No. 333-191992), March 30, 2015 (File No. 333-203097), March 14, 2016 (File No. 333-210185), March 2, 2017 (File No. 333-216388), February 28, 2018 (File No. 333-223292), February 25, 2019 (File No. 333-229848), February 25, 2020 (File No. 333-236630), February 22, 2021 (File No. 333-253363), March 1, 2022 (File No. 333-263116) and March 1, 2023 (File No. 333-270147), in each case as amended by a Post-Effective Amendment No. 1 thereto filed with the Commission on June 8, 2023, and (ii) the Registrant’s Registration Statements on Form S-8 filed with the Commission on June 12, 2024 (File No. 333-280150) and June 17, 2025 (File No. 333-288113), in each case, to the extent not superseded hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.
    The following documents filed by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:
    (a)    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on February 26, 2026;
    (b)    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above (other than the portions of these documents not deemed to be filed); and
    (c)    The description of the Registrant’s common stock contained in Registrant’s registration statement on Form 8-A, filed with the Commission on October 28, 2013 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 26, 2026.

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding any portions thereof furnished by the Registrant, including information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. § 1350), subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.





    Item 8.Exhibits.
    The following exhibits are filed herewith:

    Incorporated by Reference
    Exhibit No.DescriptionFormFile No.ExhibitFiling DateFiled Herewith
    4.1
    Restated Certificate of Incorporation of the Registrant
    8-K001-361563.26/9/2023
    4.2
    Amended and Restated Bylaws of the Registrant
    10-Q001-361563.25/6/2026
    4.3
    Form of Common Stock Certificate
    S-1/A333-1912824.110/15/2013
    5.1
    Opinion of Morrison & Foerster LLP
    X
    23.1
    Consent of Independent Registered Public Accounting Firm
    X
    23.2
    Consent of Morrison & Foerster LLP (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney (contained on signature page hereto).
    X
    99.1
    2023 Equity Incentive Plan, as amended
    DEF 14-A001-36156Appendix A4/22/2026
    99.2
    Form of agreements under the 2023 Equity Incentive Plan
    S-8 POS333-27014799.66/8/2023
    107.1
    Filing Fee Table
    X







    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of South San Francisco, State of California, on the 10th day of June 2026.
    VERACYTE, INC.
    By:/s/ MARC STAPLEY
    Marc Stapley
    Chief Executive Officer and Director






    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marc Stapley and Rebecca Chambers and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement on Form S-8, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ MARC STAPLEYChief Executive Officer and Director
    (Principal Executive Officer)
    June 10, 2026
    Marc Stapley
    /s/ REBECCA CHAMBERSChief Financial Officer
    (Principal Financial Officer)
    June 10, 2026
    Rebecca Chambers
    /s/ JONATHAN WYGANTChief Accounting Officer (Principal Accounting Officer)June 10, 2026
    Jonathan Wygant
    /s/ ROBERT S. EPSTEIN, M.D., M.S.Chairperson and DirectorJune 10, 2026
    Robert S. Epstein, M.D., M.S.
    /s/ ELIAV BARR, M.D.DirectorJune 10, 2026
    Eliav Barr, M.D.
    /s/ MUNA BHANJIDirectorJune 10, 2026
    Muna Bhanji
    /s/ KARIN EASTHAMDirectorJune 10, 2026
    Karin Eastham
    /s/ JENS HOLSTEINDirectorJune 10, 2026
    Jens Holstein
    /s/ EVAN JONESDirectorJune 10, 2026
    Evan Jones
    /s/ TOM MILLERDirectorJune 10, 2026
    Tom Miller
    /s/ BRENT SHAFERDirectorJune 10, 2026
    Brent Shafer


    Get the next $VCYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    6/2/2026$55.00Outperform
    Wolfe Research
    4/13/2026$45.00Buy
    Jefferies
    12/2/2025$48.00Underweight
    Morgan Stanley
    10/20/2025$40.00Hold
    Canaccord Genuity
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    More analyst ratings

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Veracyte with a new price target

    Wolfe Research resumed coverage of Veracyte with a rating of Outperform and set a new price target of $55.00

    6/2/26 8:39:26 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Veracyte with a new price target

    Jefferies initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    4/13/26 9:01:55 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on Veracyte with a new price target

    Morgan Stanley resumed coverage of Veracyte with a rating of Underweight and set a new price target of $48.00

    12/2/25 8:36:20 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eastham Karin sold $197,234 worth of shares (3,729 units at $52.89) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 15,097 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    6/22/26 4:30:54 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Director Eastham Karin was granted 5,272 shares, increasing direct ownership by 39% to 18,826 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    6/15/26 4:56:17 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Director Jones Evan/ Fa was granted 5,272 shares, increasing direct ownership by 18% to 34,634 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    6/15/26 4:56:12 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Veracyte Names Kevin Haas as Chief Development and Technology Officer

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief De

    3/16/26 4:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

    Genomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies 10-year risk of recurrence to help personalize treatment decisions in patients with early-stage breast cancer On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient's ROR score a

    6/1/26 7:30:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

    Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate's utility in high-risk localized disease Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy (ADT plus enzalutamide), known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1 evidence for a genomic test guiding this d

    5/30/26 8:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

    Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spared chemotherapy without compromising outcomes Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the ASCO Annual Meeting, conc

    5/29/26 3:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    SEC Filings

    View All

    SEC Form 144 filed by Veracyte Inc.

    144 - VERACYTE, INC. (0001384101) (Subject)

    6/18/26 4:23:20 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Veracyte Inc.

    S-8 - VERACYTE, INC. (0001384101) (Filer)

    6/10/26 4:17:11 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

    SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

    6/5/26 10:13:06 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Financials

    Live finance-specific insights

    View All

    Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal investigators of OPTIMA, Professor of Breast Oncology at the University of Glasgow and Honorary Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, will join for the discussion. The conference call will be webcast live

    5/22/26 8:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces First Quarter 2026 Financial Results

    Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. "We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets," said Marc Stapley, Veracyte's CEO. "Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launc

    5/5/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/even

    4/14/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veracyte Inc.

    SC 13G - VERACYTE, INC. (0001384101) (Subject)

    11/12/24 9:30:49 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    11/8/24 10:41:07 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    10/2/24 2:12:30 PM ET
    $VCYT
    Medical Specialities
    Health Care